Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 1, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 2, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001159036-26-000046
Filed / recorded
Apr 2, 2026, 10:28 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HALOZYME THERAPEUTICS, INC.
Issuer CIK
1159036
Ticker
HALO
Reporting person
Helen Torley
Relationship
Director, Officer
Officer title
PRESIDENT AND CEO
Security
Option to Purchase Common Stock
Table
Derivative (Table II)
Transaction date
Apr 1, 2026
Transaction code
M
Shares / units
20,000
Price per share
$12.07
Acquired / disposed
Disposed (D)
Shares owned after
131,923
Ownership form
Direct
Amendment
No
Footnotes from the filing
The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.